{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:34:04Z","timestamp":1792661644245,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.eururo.2011.03.017","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T16:09:06Z","timestamp":1302624546000},"page":"997-1008","source":"Crossref","is-referenced-by-count":621,"title":["EAU Guidelines on Non\u2013Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update"],"prefix":"10.1016","volume":"59","author":[{"given":"Marko","family":"Babjuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Oosterlinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"B\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palou-Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.03.017_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0010","unstructured":"Oxford Centre for Evidence-based Medicine - levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http:\/\/www.cebm.net\/index.aspx?o=1025."},{"key":"10.1016\/j.eururo.2011.03.017_bib0015","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM. Globcan 2002, cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, v.2.0. Lyon, France: IARCC Press, 2004."},{"key":"10.1016\/j.eururo.2011.03.017_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.07239.x","article-title":"Declining mortality from bladder cancer in Europe","volume":"101","author":"Ferlay","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.017_bib0025","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/oem.58.9.590","article-title":"Occupational risk factors for male bladder cancer: results from a population-based case cohort study in the Netherlands","volume":"58","author":"Zeegers","year":"2001","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.eururo.2011.03.017_bib0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q","article-title":"The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies","volume":"89","author":"Zeegers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.03.017_bib0035","series-title":"TNM classification of malignant tumors (UICC International Union Against Cancer)","first-page":"262","year":"2009"},{"key":"10.1016\/j.eururo.2011.03.017_bib0040","series-title":"WHO classification of tumours of the urinary system and male genital organs","article-title":"Tumours of the urinary system: non-invasive urothelial neoplasias","author":"Sauter","year":"2004"},{"key":"10.1016\/j.eururo.2011.03.017_bib0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non\u2013muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0050","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1309\/AJCP12MRVVHTCKEJ","article-title":"Prognostic significance of the 2004 WHO\/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases","volume":"133","author":"Pan","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0055","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0060","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"Van der Meijden","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2011.03.017_bib0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.017_bib0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumors","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0075","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 6A","key":"10.1016\/j.eururo.2011.03.017_bib0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.017_bib0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eursup.2009.06.008","article-title":"Cytology and urinary markers for the diagnosis of bladder cancer","volume":"8","author":"van Rhijn","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.017_bib0095","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2011.03.017_bib0100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2011.03.017_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00345-007-0223-2","article-title":"Screening for bladder cancer: a perspective","volume":"26","author":"Lotan","year":"2008","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: a systematic review","volume":"47","author":"Van Rhijn","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2003.09.018","article-title":"Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta,T1 bladder tumors: a report of the EORTC Genito-Urinary Tract Cancer Cooperative Group","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2009.11.041","article-title":"Photodynamic diagnosis in non\u2013muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies","volume":"57","author":"Kausch","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2009.10.030","article-title":"Transurethral resection of non\u2013muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study","volume":"57","author":"Schumacher","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","article-title":"A second-look TUR in T1 transitional cell carcinoma: why?","volume":"45","author":"Jakse","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0160","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0165","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0170","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Gu\u00e9rin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0175","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2011.03.017_bib0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2010.03.032","article-title":"Clinical outcomes of primary bladder carcinoma in situ in a contemporary series","volume":"184","author":"Chade","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0185","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","article-title":"A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences","volume":"179","author":"Berrum-Svennung","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0195","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0205","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non\u2013muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?","volume":"46","author":"Oddens","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0215","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","volume":"156","author":"Pawinski","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0225","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2011.03.017_bib0230","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0235","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.03.017_bib0240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.017_bib0250","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.017_bib0255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.017_bib0260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0275","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0285","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0290","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.017_bib0295","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0300","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0305","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Gu\u00e9rin (27mg) versus very low-dose bacillus Calmette-Gu\u00e9rin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increase toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0315","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy\u2013associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.017_bib0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Gu\u00e9rin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2011.03.017_bib0325","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.017_bib0330","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Gu\u00e9rin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0335","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0345","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0355","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.017_bib0360","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)65168-3","article-title":"Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression","volume":"176","author":"Holmang","year":"2002","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811002600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811002600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T02:57:45Z","timestamp":1712372265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811002600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0302283811002600"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.03.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}